Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The COVID-19 disease, caused by SARS-CoV-2 virus, started in December 2019 and created a pandemic with high mortality and morbidity. Since a fully proven treatment has not been developed, the efficacy of currently available treatments is being investigated. Famotidine, an H2Receptor blocker, is one of the drug treatments being investigated. In this study, we aimed to investigate the effect of Famotidine treatment on the clinic and mortality of Covid-19 patients treated in the intensive care unit.
The computer and written records of the patients followed in the Covid-19 Intensive Care Units of a research hospital during the pandemic process will be examined. Patients over the age of 18 who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR (Polymeraze Chaine Reaction) will be included in the study. Patients with immunosuppression, end-stage renal disease, liver disease, G6PD deficiency, ALT/AST >5, long QT syndrome in ECG, diagnosed with psoriasis, porphyria, pregnant, and allergic reactions to famotidine or similar drugs were excluded from the study. Patients' age, gender, comorbidities, smoking and APACHE II score will be recorded. Patients who were administered Famotidine 160 mg/day PO or nasogastric and were not given this treatment since their admission to the intensive care unit will be compared. The primary outcome will be the need for invasive mechanical ventilation, intensive care mortality, and both. As a secondary outcome, serum markers indicating the severity of the disease (Leukocytes, lymphocytes, neutrophils/leukocytes, platelets, ferritin, CRP, D-Dimer, fibrinogen, procalcitonin, IL-6, troponin, creatinine, AST, ALT, P/F ratio and lactate) will be recorded.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Famotidine Group | Patients who were administered Famotidine 160 mg/day PO or nasogastric. |
| |
| Control Group | Patients who were not administered Famotidine |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Famotidine Tablets | Drug | 160 mg/day Famotidine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients who died in intensive care | Mortality in intensive care | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| Number of patients who were intubated in intensive care | Development of respiratory distress requiring intubation in the patient | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| Measure | Description | Time Frame |
|---|---|---|
| Ferritin | Ferritin in nonogram/miiliter | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| CRP | C-Reactive protein in miligram/liter |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The patients followed in the Covid-19 Intensive Care Units
Not provided
| Name | Affiliation | Role |
|---|---|---|
| mesure Gul Nihan Ozden, MD | Istanbul Medeniyet University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istanbul Medeniyet University | Istanbul | 34730 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D015738 | Famotidine |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
Not provided
Not provided
Not provided
Not provided
Not provided
| Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| D-Dimer | D-Dimer in nonogram/miiliter | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| Fibrinogen | Fibrinogen in nonogram/miiliter | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| Procalcitonin | Procalcitonin in nonogram/miiliter | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |